Georg Schett

ORCID: 0000-0001-8740-9615
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Rheumatoid Arthritis Research and Therapies
  • Spondyloarthritis Studies and Treatments
  • Bone Metabolism and Diseases
  • Autoimmune and Inflammatory Disorders Research
  • Systemic Lupus Erythematosus Research
  • Systemic Sclerosis and Related Diseases
  • Psoriasis: Treatment and Pathogenesis
  • Bone and Joint Diseases
  • Bone health and treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Osteoarthritis Treatment and Mechanisms
  • Cytokine Signaling Pathways and Interactions
  • T-cell and B-cell Immunology
  • Cell Adhesion Molecules Research
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Inflammasome and immune disorders
  • Dermatologic Treatments and Research
  • Immune Response and Inflammation
  • Bone health and osteoporosis research
  • Vasculitis and related conditions
  • IL-33, ST2, and ILC Pathways
  • Inflammatory mediators and NSAID effects
  • Chronic Lymphocytic Leukemia Research

Friedrich-Alexander-Universität Erlangen-Nürnberg
2016-2025

Universitätsklinikum Erlangen
2016-2025

Bayer (Germany)
2017-2025

Center for Rheumatology
2010-2024

University of the Sacred Heart
2024

Università Cattolica del Sacro Cuore
2024

Istituti di Ricovero e Cura a Carattere Scientifico
2024

Otto-von-Guericke University Magdeburg
2024

German Center for Neurodegenerative Diseases
2024

German Climate Computing Centre
2020-2024

Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of is associated with side effects. The effect interleukin-6 receptor alpha inhibitor tocilizumab on rates relapse during glucocorticoid tapering was studied in patients giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, a 2:1:1:1 ratio, to receive subcutaneous (at dose 162 mg) weekly or every other week, combined 26-week prednisone taper, placebo taper over period either...

10.1056/nejmoa1613849 article EN New England Journal of Medicine 2017-07-26

Background Since the publication of European League Against Rheumatism recommendations for pharmacological treatment psoriatic arthritis (PsA) in 2012, new evidence and therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review performed regarding PsA. Subsequently, were formulated based on expert opinion 34 Task Force members. Levels strengths allocated. Results updated comprise 5 overarching principles 10 recommendations,...

10.1136/annrheumdis-2015-208337 article EN Annals of the Rheumatic Diseases 2015-12-07

To update the European League Against Rheumatism (EULAR) recommendations for pharmacological treatment of psoriatic arthritis (PsA).According to EULAR standardised operating procedures, a systematic literature review was followed by consensus meeting develop this involving 28 international taskforce members in May 2019. Levels evidence and strengths were determined.The updated comprise 6 overarching principles 12 recommendations. The address nature PsA diversity both musculoskeletal...

10.1136/annrheumdis-2020-217159 article EN cc-by-nc Annals of the Rheumatic Diseases 2020-05-20

The transforming growth factor-β (TGF-β) signalling pathway is a key mediator of fibroblast activation that drives the aberrant synthesis extracellular matrix in fibrotic diseases. Here we demonstrate novel link between and canonical Wnt pathway. TGF-β stimulates p38-dependent manner by decreasing expression antagonist Dickkopf-1. Tissue samples from human diseases show enhanced proteins decreased Activation fibroblasts vitro induces fibrosis vivo. Transgenic overexpression Dickkopf-1...

10.1038/ncomms1734 article EN cc-by-nc-nd Nature Communications 2012-03-13

Autoimmunity is complicated by bone loss. In human rheumatoid arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citrullinated proteins are among strongest risk factors for destruction. We therefore hypothesized that these directly influence metabolism. Here, we found a strong and specific association between serum markers osteoclast-mediated resorption in RA patients. Moreover, osteoclasts expressed enzymes eliciting protein citrullination, N-terminal...

10.1172/jci60975 article EN Journal of Clinical Investigation 2012-04-16

The detailed cellular and molecular mechanisms leading to joint destruction in rheumatoid arthritis, a disease driven by proinflammatory cytokines, are still unknown. To address the question of whether osteoclasts play pivotal role this process, transgenic mice that express human TNF (hTNFtg) develop severe destructive arthritis were crossed with osteopetrotic, c-fos–deficient (c-fos–/–) completely lacking osteoclasts. resulting mutant (c-fos–/–hTNFtg) developed TNF-dependent absence All...

10.1172/jci15582 article EN Journal of Clinical Investigation 2002-11-15

Microbial metabolites are known to modulate immune responses of the host. The main derived from microbial fermentation dietary fibers in intestine, short-chain fatty acids (SCFA), affect local and systemic functions. Here we show that SCFA regulators osteoclast metabolism bone mass vivo. Treatment mice with as well feeding a high-fiber diet significantly increases prevents postmenopausal inflammation-induced loss. protective effects on associated inhibition differentiation resorption vitro...

10.1038/s41467-017-02490-4 article EN cc-by Nature Communications 2017-12-29

Autoantibodies against double-stranded DNA (dsDNA) and nucleosomes represent a hallmark of systemic lupus erythematosus (SLE). However, the mechanisms involved in breaking immunological tolerance these poorly immunogenic nuclear components are not fully understood. Impaired phagocytosis apoptotic cells with consecutive release antigens may contribute to immune pathogenesis. The architectural chromosomal protein proinflammatory mediator high mobility group box 1 (HMGB1) is tightly attached...

10.1084/jem.20081165 article EN The Journal of Experimental Medicine 2008-12-08

Osteoprotegerin is a novel member of the tumor necrosis factor receptor superfamily and soluble decoy activator nuclear factor-kappaB ligand. Recent experimental research has implicated osteoprotegerin in atherogenesis, but epidemiological confirmation this concept sparse.As part prospective, population-based Bruneck Study, severity, initiation, progression atherosclerosis were assessed carotid arteries. Cases incident cardiovascular disease vascular mortality carefully recorded over 10-year...

10.1161/01.cir.0000127957.43874.bb article EN Circulation 2004-04-27

The detailed cellular and molecular mechanisms leading to joint destruction in rheumatoid arthritis, a disease driven by proinflammatory cytokines, are still unknown. To address the question of whether osteoclasts play pivotal role this process, transgenic mice that express human TNF (hTNFtg) develop severe destructive arthritis were crossed with osteopetrotic, c-fos–deficient (c-fos–/–) completely lacking osteoclasts. resulting mutant (c-fos–/–hTNFtg) developed TNF-dependent absence All...

10.1172/jci0215582 article EN Journal of Clinical Investigation 2002-11-15

Background —Work from our laboratory has proven that increased titers of anti-heat shock protein 60 (HSP60) antibodies are associated with atherosclerosis and HSP60-reactive T-cells present in atherosclerotic lesions. Recent studies others demonstrated HSP60 directly activates endothelial cells macrophages. Methods Results —To explore the possibility exists circulation, where it could exert its functions, we performed a population-based study 826 subjects aged 40 to 79 years. The following...

10.1161/01.cir.102.1.14 article EN Circulation 2000-07-04
Coming Soon ...